RBCG30: Difference between revisions
Content deleted Content added
m Added 1 doi to a journal cite using AWB (10201) |
|||
| Line 1: | Line 1: | ||
{{Unreferenced stub|auto=yes|date=December 2009}} |
{{Unreferenced stub|auto=yes|date=December 2009}} |
||
'''rBCG30''' ('''recombinant [[Bacillus Calmette-Guérin]] 30''') is a prospective [[vaccine]] against [[tuberculosis]] created by a team headed by [[Marcus A. Horwitz]] at [[University of California, Los Angeles|UCLA]]. It is a live vaccine, consisting of [[Bacillus Calmette-Guerin|BCG]] genetically modified to produce abundant amounts of a 30[[Wiktionary:kilodalton|kDa]] antigen (Antigen 85B) that has been shown to produce a strong immune response in animals<ref>{{cite journal |author=Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S |title=Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=97 |issue=25 |pages=13853–8 |date=December 2000 |pmid=11095745 |pmc=17665 |doi=10.1073/pnas.250480397 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=11095745}}</ref><ref>{{cite journal |author=Horwitz MA, Harth G |title=A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis |journal=Infect. Immun. |volume=71 |issue=4 |pages=1672–9 |date=April 2003 |pmid=12654780 |pmc=152073 |url=http://iai.asm.org/cgi/pmidlookup?view=long&pmid=12654780}}</ref><ref>{{cite journal |author=Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S |title=Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity |journal=Vaccine |volume=24 |issue=4 |pages=443–51 |date=January 2006 |pmid=16125825 |doi=10.1016/j.vaccine.2005.08.001 |url=http://linkinghub.elsevier.com/retrieve/pii/S0264-410X(05)00781-4}}</ref><ref>{{cite journal |author=Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S |title=A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG |journal=Vaccine |volume=24 |issue=10 |pages=1593–600 |date=March 2006 |pmid=16257099 |doi=10.1016/j.vaccine.2005.10.002 |url=http://linkinghub.elsevier.com/retrieve/pii/S0264-410X(05)01037-6}}</ref> and humans. The vaccine completed a Phase I double-blind randomized controlled clinical trial that demonstrated that rBCG30 was safe and immunogenic; during nine months of follow-up, rBCG30, but not BCG, induced significantly increased Antigen 85B-specific immune responses in eight immunological assays (blood lymphocyte proliferation, antibody responses by [[ELISA]], interferon-gamma producing [[CD4|CD4+]] and [[CD8]]+ T cells ex vivo, central memory CD4+ and CD8+ T cells, interferon-gamma [[ELISPOT]] responses, and the capacity of T cells to activate macrophages to inhibit mycobacterial intracellular multiplication).<ref>{{cite journal |author=Hoft DF, Blazevic A, Abate G, ''et al.'' |title=A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers |journal=J. Infect. Dis. |volume=198 |issue=10 |pages=1491–501 |date=November 2008 |pmid=18808333 |pmc=2670060 |doi=10.1086/592450 |url=http://www.jid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=18808333}}</ref> |
'''rBCG30''' ('''recombinant [[Bacillus Calmette-Guérin]] 30''') is a prospective [[vaccine]] against [[tuberculosis]] created by a team headed by [[Marcus A. Horwitz]] at [[University of California, Los Angeles|UCLA]]. It is a live vaccine, consisting of [[Bacillus Calmette-Guerin|BCG]] genetically modified to produce abundant amounts of a 30[[Wiktionary:kilodalton|kDa]] antigen (Antigen 85B) that has been shown to produce a strong immune response in animals<ref>{{cite journal |author=Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S |title=Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=97 |issue=25 |pages=13853–8 |date=December 2000 |pmid=11095745 |pmc=17665 |doi=10.1073/pnas.250480397 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=11095745}}</ref><ref>{{cite journal |author=Horwitz MA, Harth G |title=A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis |journal=Infect. Immun. |volume=71 |issue=4 |pages=1672–9 |date=April 2003 |pmid=12654780 |pmc=152073 |url=http://iai.asm.org/cgi/pmidlookup?view=long&pmid=12654780 |doi=10.1128/iai.71.4.1672-1679.2003}}</ref><ref>{{cite journal |author=Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S |title=Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity |journal=Vaccine |volume=24 |issue=4 |pages=443–51 |date=January 2006 |pmid=16125825 |doi=10.1016/j.vaccine.2005.08.001 |url=http://linkinghub.elsevier.com/retrieve/pii/S0264-410X(05)00781-4}}</ref><ref>{{cite journal |author=Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S |title=A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG |journal=Vaccine |volume=24 |issue=10 |pages=1593–600 |date=March 2006 |pmid=16257099 |doi=10.1016/j.vaccine.2005.10.002 |url=http://linkinghub.elsevier.com/retrieve/pii/S0264-410X(05)01037-6}}</ref> and humans. The vaccine completed a Phase I double-blind randomized controlled clinical trial that demonstrated that rBCG30 was safe and immunogenic; during nine months of follow-up, rBCG30, but not BCG, induced significantly increased Antigen 85B-specific immune responses in eight immunological assays (blood lymphocyte proliferation, antibody responses by [[ELISA]], interferon-gamma producing [[CD4|CD4+]] and [[CD8]]+ T cells ex vivo, central memory CD4+ and CD8+ T cells, interferon-gamma [[ELISPOT]] responses, and the capacity of T cells to activate macrophages to inhibit mycobacterial intracellular multiplication).<ref>{{cite journal |author=Hoft DF, Blazevic A, Abate G, ''et al.'' |title=A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers |journal=J. Infect. Dis. |volume=198 |issue=10 |pages=1491–501 |date=November 2008 |pmid=18808333 |pmc=2670060 |doi=10.1086/592450 |url=http://www.jid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=18808333}}</ref> |
||
==References== |
==References== |
||
Revision as of 12:11, 22 May 2014
 |
rBCG30 (recombinant Bacillus Calmette-Guérin 30) is a prospective vaccine against tuberculosis created by a team headed by Marcus A. Horwitz at UCLA. It is a live vaccine, consisting of BCG genetically modified to produce abundant amounts of a 30kDa antigen (Antigen 85B) that has been shown to produce a strong immune response in animals[1][2][3][4] and humans. The vaccine completed a Phase I double-blind randomized controlled clinical trial that demonstrated that rBCG30 was safe and immunogenic; during nine months of follow-up, rBCG30, but not BCG, induced significantly increased Antigen 85B-specific immune responses in eight immunological assays (blood lymphocyte proliferation, antibody responses by ELISA, interferon-gamma producing CD4+ and CD8+ T cells ex vivo, central memory CD4+ and CD8+ T cells, interferon-gamma ELISPOT responses, and the capacity of T cells to activate macrophages to inhibit mycobacterial intracellular multiplication).[5]
References
- ^ Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S (December 2000). "Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model". Proc. Natl. Acad. Sci. U.S.A. 97 (25): 13853–8. doi:10.1073/pnas.250480397. PMC 17665. PMID 11095745.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Horwitz MA, Harth G (April 2003). "A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis". Infect. Immun. 71 (4): 1672–9. doi:10.1128/iai.71.4.1672-1679.2003. PMC 152073. PMID 12654780.
- ^ Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S (January 2006). "Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity". Vaccine. 24 (4): 443–51. doi:10.1016/j.vaccine.2005.08.001. PMID 16125825.
{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link) - ^ Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S (March 2006). "A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG". Vaccine. 24 (10): 1593–600. doi:10.1016/j.vaccine.2005.10.002. PMID 16257099.
{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link) - ^ Hoft DF, Blazevic A, Abate G; et al. (November 2008). "A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers". J. Infect. Dis. 198 (10): 1491–501. doi:10.1086/592450. PMC 2670060. PMID 18808333.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |